Physician profile
Georgi Kovachev
NPI 1942458823
$8,720.95
in general payments reported to CMS, 2019-2025
29 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,614 · 2020: $975 · 2021: $1,332 · 2022: $1,039 · 2023: $985 · 2024: $1,392 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,522 · Consulting Fee: $150 · Education: $89.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,521.82 |
| Consulting Fee | $150.00 |
| Education | $89.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,223.07 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $881.14 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $807.23 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $743.86 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $704.97 | 2019-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $683.08 | 2020-2025 | Acthar |
| Akebia Therapeutics INC | $564.81 | 2019-2025 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $455.62 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $341.56 | 2021-2025 | |
| Travere Therapeutics, INC. | $313.52 | 2022-2024 | |
| Calliditas Therapeutics US INC. | $281.18 | 2022-2025 | Tarpeyo |
| Novo Nordisk INC | $277.66 | 2025 | Ozempic, Wegovy |
| Aurinia Pharma U.S., INC. | $226.06 | 2021-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $175.35 | 2024-2025 | |
| Shire North American Group INC | $146.59 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $126.78 | 2019-2024 | Injectafer |
| Allergan, INC. | $124.31 | 2019 | |
| Pfizer INC. | $116.06 | 2019 | |
| Horizon Therapeutics Plc | $77.41 | 2023 | Krystexxa |
| Lilly USA, LLC | $76.63 | 2024-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.02 | 2024 | Jardiance |
| Ardelyx, INC. | $51.34 | 2024 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $49.95 | 2019-2023 | Ultomiris |
| Mallinckrodt Enterprises LLC | $47.06 | 2019 | |
| Cormedix INC. | $45.37 | 2024 | Defencath |
| Scpharmaceuticals INC. | $39.19 | 2025 | |
| Glaxosmithkline, LLC. | $38.42 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $31.47 | 2022 | |
| Apellis Pharmaceuticals, INC. | $17.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georgi Kovachev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.